admin
April 15, 2026
The timeline looked brilliant. Prototype by June.Verification by September.FDA meeting by November.Submission next year. Clean. Sharp. Reassuring. Then reality showed up. One design change delayed testing.A […]
April 14, 2026
Everything looks fine until FDA responds. The roadmap is on track. The milestones are moving. The team is hitting deadlines. Then the feedback arrives. FDA wants […]
April 13, 2026
A medical device company can look perfectly organized on paper and still be heading toward a regulatory mess. The timeline may look polished.Prototype by Q2. Verification […]
April 10, 2026
The deal closed.
Capital transferred. Board seats assigned. Milestones locked in. Everyone moved on.
Then, six months later, a quiet update arrived in the investor's inbox:
"FDA has requested additional data."
Timelines shifted. Burn rate climbed. The next round became a conversation nobody wanted to have. The investment wasn't struggling because of the product — it was struggling because regulatory risk had been left unattended after the term sheet was signed.
This is more common than most investors realize.
